BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $14,636.36 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 956 shares of the stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $15.31, for a total transaction of $14,636.36. Following the transaction, the chief financial officer now directly owns 126,658 shares in the company, valued at approximately $1,939,133.98. The transaction was disclosed in a filing with the SEC, which is available through this link.

Troy Wichterman also recently made the following trade(s):

• On Thursday, March 21st, Troy Wichterman sold 520 shares of BioLife Solutions stock. The shares were sold at an average price of $17.83, for a total transaction of $9,271.60.
• On Monday, March 11th, Troy Wichterman sold 361 shares of BioLife Solutions stock. The shares were sold at an average price of $17.42, for a total transaction of $6,288.62.
• On Wednesday, February 21st, Troy Wichterman sold 97 shares of BioLife Solutions stock. The shares were sold at an average price of $17.35, for a total transaction of $1,682.95.

BioLife Solutions Stock Performance

Shares of BLFS stock traded up $0.22 during trading hours on Tuesday, hitting $17.02. 527,610 shares of the company were exchanged, compared to its average volume of 409,926. The firm has a fifty day simple moving average of $17.40 and a 200 day simple moving average of $15.39. The company has a current ratio of 2.86, a quick ratio of 1.83 and a debt-to-equity ratio of 0.06. BioLife Solutions, Inc. has a 52-week low of $8.92 and a 52-week high of $24.50. The stock has a market capitalization of $771.01 million, a price-to-earnings ratio of -11.20 and a beta of 1.67.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. The company had revenue of $32.73 million during the quarter, compared to analyst estimates of $32.70 million. Research analysts predict that BioLife Solutions, Inc. will post -0.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its stake in BioLife Solutions by 1,038.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,401,899 shares of the medical equipment provider’s stock valued at $39,031,000 after buying an additional 2,191,002 shares in the last quarter. Granahan Investment Management LLC grew its stake in BioLife Solutions by 22.8% in the 4th quarter. Granahan Investment Management LLC now owns 1,292,675 shares of the medical equipment provider’s stock valued at $21,006,000 after buying an additional 240,001 shares in the last quarter. Invesco Ltd. grew its stake in BioLife Solutions by 6.5% in the 3rd quarter. Invesco Ltd. now owns 1,052,065 shares of the medical equipment provider’s stock valued at $14,529,000 after buying an additional 64,475 shares in the last quarter. William Blair Investment Management LLC purchased a new position in BioLife Solutions in the 3rd quarter valued at approximately $9,335,000. Finally, New York State Common Retirement Fund grew its stake in BioLife Solutions by 11.9% in the 3rd quarter. New York State Common Retirement Fund now owns 419,618 shares of the medical equipment provider’s stock valued at $5,795,000 after buying an additional 44,714 shares in the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group began coverage on shares of BioLife Solutions in a research report on Thursday, April 4th. They issued a “buy” rating and a $22.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat.com, BioLife Solutions presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.40.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.